2Suppliers
1Customers
2Debt Items
0Related Chains
Evommune, Inc. Suppliers
| Ticker | Name | Confidence | Evidence |
|---|
| DERMIRA-INC |
DERMIRA-INC |
90%
|
In consideration for the licenses granted to us under the Dermira License Agreement, we paid to Dermira a $7.5 million upfront license fee. |
| DERMIRA |
DERMIRA |
80%
|
we obtained an exclusive, worldwide license to develop and commercialize certain compounds, including EVO756. |
Evommune, Inc. Customers
| Ticker | Name | Confidence | Evidence |
|---|
| MARUHO-CO-LTD |
MARUHO-CO-LTD |
90%
|
The Company recognized $ 3.0 million in license revenue for the three months ended March 31, 2025 upon the satisfaction of the performance obligation. |
Evommune, Inc. Debt Obligations
| Instrument | Description | Confidence | Evidence |
|---|
| EVMN-DEBT-14225 |
Xbrl Convertible |
90%
|
xbrl convertible detail from xbrl 2025-12-31. |
| EVMN-DEBT |
Debt stack $9.1M |
90%
|
Market cache reports total debt of $9.1M. |
Evommune, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Evommune, Inc..
Evommune, Inc. Ownership
| Holder | Name | Confidence | Evidence |
|---|
| EVMN-OWNER-EQT-FUND-MANAGEMENT-S-A-R-L |
EQT Fund Management S.a r.l. |
90%
|
13F overlay lists EQT Fund Management S.a r.l. as top holder; 84 tracked holders. |
Evommune, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
